{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:15:00Z","timestamp":1787159700481,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/crd.0b013e3181ebdb2f","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T05:36:16Z","timestamp":1281159376000},"page":"264-267","source":"Crossref","is-referenced-by-count":16,"title":["Pitavastatin"],"prefix":"10.1097","volume":"18","author":[{"given":"Haniyyah","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cheng-Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1253\/circj.CJ-08-1051","article-title":"Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque: comparison with atorvastatin.","volume":"73","author":"Toi","year":"2009","journal-title":"Circ J"},{"key":"R2-7-20210203","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.CIR.99.2.185","article-title":"Natural statins and stroke risk.","volume":"99","author":"Furberg","year":"1999","journal-title":"Circulation"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1742-1241.2005.00461.x","article-title":"Pitavastatin.","volume":"59","author":"Mukhtar","year":"2005","journal-title":"Int J Clin Pract"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","article-title":"Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) Study.","volume":"54","author":"Hiro","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R12-7-20210203","first-page":"1477","article-title":"Pitavastatin in the management of hypercholesterolemia.","volume":"1","author":"Nomura","year":"2009","journal-title":"Clin Med: Ther"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5551\/jat1994.7.138","article-title":"Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.","volume":"7","author":"Morikawa","year":"2000","journal-title":"J Atheroscler Thromb"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1291\/hypres.25.279","article-title":"Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin.","volume":"25","author":"Kohno","year":"2002","journal-title":"Hypertens Res"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/009127002401102731","article-title":"Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.","volume":"42","author":"Igel","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1517\/13543784.9.11.2653","article-title":"NK-104: a novel synthetic HMG-CoA reductase inhibitor.","volume":"9","author":"Kajinami","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","article-title":"Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study.","volume":"110","author":"Okazaki","year":"2004","journal-title":"Circulation"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1345\/aph.1M522","article-title":"Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.","volume":"44","author":"Sansanayudh","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3909\/ricm0535","article-title":"Pitavastatin: the newest HMG-CoA reductase inhibitor.","volume":"11","author":"Watson","year":"2010","journal-title":"Rev Cardiovasc Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0b013e3181ebdb2f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:34:19Z","timestamp":1786041259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201009000-00007"}},"subtitle":["A New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia"],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e3181ebdb2f","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}